Pancreatic Cancer Pain: Celiac Plexus Neurolysis Now, or Keep Escalating Opioids?
A modest trial benefit for a procedure that slows opioid escalation rather than replacing it forces a real question about how much invasive intervention is worth pursuing for pain that conservative titration is, for now, still managing.
Edmund S. taught high-school history for thirty-nine years and has spent most of his retirement volunteering at the same school's archive, sorting decades of yearbooks and photographs he says nobody else has the patience for. His pancreatic adenocarcinoma, diagnosed four months ago, is unresectable — involving the celiac axis on imaging at diagnosis — and he is currently on systemic chemotherapy with a goal of disease control rather than cure, a distinction he's been direct about understanding clearly. His pain, a deep, boring epigastric and mid-back ache characteristic of retroperitoneal tumor involvement, has required steady opioid escalation over the past two months, currently on a moderate oral morphine equivalent dose that controls his pain reasonably but leaves him drowsy enough most afternoons that he's stopped going to the archive as often as he used to.
He is not failing his current regimen in the sense of uncontrolled pain — his numbers are acceptable most days — but the sedation and constipation that have come with escalating doses are costing him real function, the specific kind he's said matters most to him. Celiac plexus neurolysis targets the same visceral afferent pathway carrying his pain signal directly, and the one randomized trial testing it in pancreatic cancer (Wyse et al., 2011) found significantly greater pain relief at three months than usual care, with morphine consumption trending lower without reaching statistical significance, and no survival or quality-of-life benefit at all. Read honestly, the trial carries the pain claim and only gestures at the opioid-sparing one — which is the claim that would actually matter for him, since it is the sedation and not the pain score that has taken his afternoons.
He brought a specific example to this visit rather than a general complaint: two weeks ago he'd slept through most of an afternoon he'd set aside to catalog a box of 1970s yearbooks a former student's family had just donated, waking only when the archive closed for the day. He described it not with anger but with a kind of quiet grief, noting that he has, by his own estimate, a limited number of these afternoons left and doesn't want to spend them asleep. His oncologist has taken that specific account seriously as its own kind of data, distinct from his pain score on any given day.
Clinic, reviewing his pain regimen
I'd pursue celiac plexus neurolysis now rather than keep escalating opioids. The randomized trial evidence (Wyse et al., 2011) found significantly greater pain relief at three months than usual care, with morphine consumption trending lower without reaching significance — I'll concede the opioid-sparing signal is a trend and not a result, but it points the direction that matters for him, given that his sedation, not his pain score, is what's actually taking time away from the archive work he's told us matters most.
I'd be more cautious. That same trial showed no survival or quality-of-life benefit at all, and the opioid-escalation finding you're leaning on didn't reach significance either, and neurolysis is an invasive procedure with its own real, if uncommon, complication profile — he isn't currently failing conservative titration, his pain control is acceptable most days. Continuing to titrate systemic therapy, with risks we already understand well, is a reasonable default before adding a procedural intervention.
I'll grant that his side-effect burden, not his pain score, is the real functional problem here — that's a genuine argument for reconsidering, not something I'd dismiss. I'd want to try an opioid-sparing adjunct first, though, before an invasive step neither of us can fully undo.
Agreed: duloxetine added now as an opioid-sparing trial, his morphine dose held steady, with a four-week reassessment already scheduled to judge whether neurolysis should move forward.
Not agreed: how much weight his functional priorities, rather than his pain score alone, should carry in that four-week decision. The palliative care specialist wants his own stated priority — staying alert enough for the archive work — to be the explicit deciding measure; the oncologist wants a more conventional pain-and-function composite, worried that over-weighting one specific activity risks a decision that doesn't generalize as his disease progresses.